Oncology Central

Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies


Encouraging data from the clinical trials of inhibiting programmed cell death-1 (PD-1)/programmed death-ligand (PD-L) pathway in recent years suggests improvement in the efficiency of immunotherapy in lung cancer. The interaction between PD-1 and its ligands, PD-L1 and PD-L2 as the second signal of the activation of T cells leads to the downregulation of T-cell responses and inhibit cytokine production.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.